Acute inflammation is defined as a CRP ≥ 10 mg/l. We will include 2 groups of participants:
A group with an inflammatory syndrome and infection; infection being defined as:
Viral infection confirmed by nasopharynx swab for: influenza, RSV, parainfluenza, rhinovirusses, coronavirusses.
Bacterial infection confirmed with positive blood culture, positive articular punction, positive expectorations, pneumonia on chest radiograph, or infection documented by abdominal imagery (CT or echo), a positive urine culture with a confirmed pyelonephritis with a renal echography or a DMSA scintigraphy or specific clinical symptoms for pyelonephritis and positive hemoculture. A positive urine culture alone is not considered as urine infection because of the high prevalence of asymptomatic bacteriuria in geriatric patients.

Acute inflammation is defined as a CRP ≥ 10 mg/l. We will include 2 groups of participants:
=> B) A group with inflammatory syndrome and inflammatory diseases without infection: defined as:
Confirmed pulmonary embolism (PE) by CT or ventilation-perfusion scintigraphy
Microcrystalline arthritis diagnosed by articular punction
Crush syndrome or rhabdomyolyses defined by history of a fall and raised creatine kinase in blood sample.

White Blood Cells Engulfing Red Blood Cells

No intervention, observational study

Usefulness of White Blood Cell Count (WBCC) During Infection in Geriatric Patient

Usefulness of White Blood Cell Count (WBCC) During Infection: a Comparison Between Hospitalized Geriatric and Young Groups.

observation of WBCC is correlated with infection by older patient

data will be maybe described in an article

Nathalie compté

Clinic head of geriatric unit

Universitair Ziekenhuis Brussel

Rosuvastatin
Rosuvastatin: Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days

Rosuvastatin

Placebo
Placebo: Placebo administered every day for up to 28 days

Placebo

Total

Sex: Female, Male

Primary Endpoint: Reduction in CRP Level Over Time, Compared to Placebo Measured at Baseline and Days 3, 7, 14. The Mean CRP Levels at Specified Days Will be the Endpoints.

Mortality Compared to Placebo

Mortality Compared to Placebo, Adjusted for Cardiovascular Co-morbidities

Reduction in the Incidence of Septic Shock (See Definition) Compared to Placebo

Reduction in the Incidence of Septic Shock (See Definition) Compared to Placebo, Adjusted for Cardiovascular Co-morbidities

A Reduction in CK Levels Over Time, Compared to Placebo Measured at Baseline and Days 3, 7, 14, 21, 28

A Reduction in ALT Levels Over Time, Compared to Placebo, Measured at Baseline, Days 1, 7, 14, 21, 28

Determine the Safety of Rosuvastatin Compared to Placebo in Burn Patients by Comparing the Frequency, Type and Severity of Adverse Events

Determine Which Are Appropriate Attainable Endpoints for Future Trials and the Number of Participants Required to Reach Significance in Analysis of a Variety of Variables

rhabdomyolysis/albumin

Usefulness of White Blood Cell Count (WBCC) During Infection in Geriatric Patient

Pilot Trial of Statin Use in Burn Patients

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen